Baillie Gifford & Co
UTHR icon

Baillie Gifford & Co’s United Therapeutics UTHR Stock Holding History

Baillie Gifford & Co’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$253M Buy
467,209
+39,082
+9% +$22M 0.23% 89
2026
Q1 		$254M Buy
428,127
+105,111
+33% +$52.3M 0.26% 77
2025
Q4 		$157M Buy
+323,016
New +$150M 0.13% 111

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Baillie Gifford & Co's UTHR Position: Q2 2026 in Review

Baillie Gifford & Co increased its United Therapeutics (UTHR) stake by 9.1% in Q2 2026, buying an estimated $22M and bringing the position to 467,209 shares worth $253M. The position accounts for 0.23% of the portfolio, ranked #89.

Baillie Gifford & Co first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $254M in Q1 2026. 879 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Baillie Gifford & Co held 467,209 shares of United Therapeutics worth $253M as of Q2 2026.
  • Baillie Gifford & Co bought 39,082 United Therapeutics shares in Q2 2026, an estimated $22M.
  • United Therapeutics made up 0.23% of Baillie Gifford & Co's portfolio in Q2 2026, its #89 holding.
  • Baillie Gifford & Co first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Baillie Gifford & Co's United Therapeutics position peaked at $254M in Q1 2026.
  • 879 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.